Processes for preparing an FGFR inhibitor

Patent metadata

Field	Value
Publication number	US-12281110-B2
Application number	US-202117155726-A
Country	US
Kind code	B2
Filing date	Jan 22, 2021
Priority date	Aug 11, 2015
Publication date	Apr 22, 2025
Grant date	Apr 22, 2025

Abstract

Disclosed herein are processes for preparing 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one and FGFR inhibitor, as well as polymorphs and/or salt forms thereof.

First claim

What is claimed:

1. A crystalline free base of a compound of formula:

2. The crystalline free base according to claim 1 , characterized by an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about 22° 2Θ.

3. The crystalline free base according to claim 1 , wherein the free base is in a substantially anhydrous form.

4. The crystalline free base according to claim 1 , wherein the free base is in a hydrate form.

5. The crystalline free base according to claim 4 , characterized by an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about 6° 2Θ.

6. The crystalline free base according to claim 1 , wherein the free base is in a solvate form.

7. The crystalline free base according to claim 6 , wherein the solvate is at least one of an acetonitrile solvate, an acetone solvate, and a dichloromethane solvate.

8. The crystalline free base according to claim 6 , characterized by an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about 14° 2Θ.

9. An amorphous free base of a compound of formula:

10. The amorphous free base according to claim 9 , characterized by an X-ray powder diffraction (XRPD) pattern comprising a characteristic disordered halo at about 23° 2Θ.

11. A crystalline hydrochloride salt or a crystalline maleate salt of a compound of formula:

12. The crystalline salt according to claim 11 , wherein the crystalline salt is a crystalline hydrochloride salt.

13. The crystalline hydrochloride salt according to claim 12 , characterized by an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about 11° 2Θ.

14. The crystalline salt according to claim 11 , wherein the crystalline salt is a crystalline maleate salt.

15. The crystalline maleate salt according to claim 14 , characterized by an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about 22.5° 2Θ.

16. A pharmaceutical composition comprising the crystalline free base of claim 1 , and a pharmaceutically acceptable carrier and/or excipient.

17. A pharmaceutical composition comprising the amorphous free base of claim 9 , and a pharmaceutically acceptable carrier and/or excipient.

18. A pharmaceutical composition comprising the crystalline hydrochloride salt of claim 12 , and a pharmaceutically acceptable carrier and/or excipient.

19. A pharmaceutical composition comprising the crystalline maleate salt of claim 14 , and a pharmaceutically acceptable carrier and/or excipient.

Assignees

• Principia Biopharma Inc

Inventors

• Zhu Jiang
• Masjedizadeh Mohammad

Classifications

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• C07B45/04

  of sulfonyl or sulfinyl groups · CPC title

• C07B43/06

  of amide groups · CPC title

• C07B43/04

  of amino groups · CPC title

• C07B39/00

  Halogenation · CPC title